[S02DA03, antipyrine, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Antipyrine is combined with Eplerenone.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Eplerenone.]
[J01GA01, streptomycin, Eplerenone may increase the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[M03AB01, succinylcholine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Eplerenone.]
[A02BX02, sucralfate, Eplerenone may increase the excretion rate of Sucralfate which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CG01, sulbactam, Eplerenone may increase the excretion rate of Sulbactam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01EC02, sulfadiazine, Eplerenone may increase the excretion rate of Sulfadiazine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01EC01, sulfamethoxazole, Eplerenone may increase the excretion rate of Sulfamethoxazole which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AB02, sulindac, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Eplerenone.]
[M01AX04, apazone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azapropazone is combined with Eplerenone.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Eplerenone.]
[N05CD07, temazepam, Eplerenone may increase the excretion rate of Temazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Eplerenone.]
[R03CC03, terbutaline, Eplerenone may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AE07, dabigatran etexilate, Eplerenone may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.]
[G03BA03, testosterone, Eplerenone may increase the excretion rate of Testosterone which could result in a lower serum level and potentially a reduction in efficacy.]
[S03AA02, tetracycline, Eplerenone may increase the excretion rate of Tetracycline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AE05, lurasidone, Lurasidone may decrease the antihypertensive activities of Eplerenone.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Eplerenone is combined with Apomorphine.]
[L04AX02, thalidomide, The metabolism of Eplerenone can be increased when combined with Thalidomide.]
[P02CA02, thiabendazole, Eplerenone may increase the excretion rate of Thiabendazole which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AD03, thiethylperazine, Eplerenone may increase the excretion rate of Thiethylperazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Eplerenone.]
[N05AB08, thioproperazine, Thioproperazine may decrease the antihypertensive activities of Eplerenone.]
[N05AC02, thioridazine, Thioridazine may decrease the antihypertensive activities of Eplerenone.]
[G04BE06, moxisylyte, Eplerenone may increase the excretion rate of Moxisylyte which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL03, tiapride, Eplerenone may increase the excretion rate of Tiapride which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC05, ticlopidine, Eplerenone may increase the excretion rate of Ticlopidine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX01, tilidine, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Tilidine.]
[S01ED01, timolol, Eplerenone may increase the excretion rate of Timolol which could result in a lower serum level and potentially a reduction in efficacy.]
[P01AB02, tinidazole, Eplerenone may increase the excretion rate of Tinidazole which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA12, tobramycin, Eplerenone may increase the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BB05, tolazamide, Eplerenone may increase the excretion rate of Tolazamide which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AX02, tolazoline, Tolazoline may decrease the antihypertensive activities of Eplerenone.]
[V04CA01, tolbutamide, Eplerenone may increase the excretion rate of Tolbutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA21, tolmetin, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolmetin is combined with Eplerenone.]
[N02AX02, tramadol, Eplerenone may increase the excretion rate of Tramadol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the hypotensive activities of Eplerenone.]
[N06AX05, trazodone, Trazodone may decrease the antihypertensive activities of Eplerenone.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Eplerenone is combined with Tretinoin.]
[S01BA05, triamcinolone, The metabolism of Eplerenone can be increased when combined with Triamcinolone.]
[C03DB02, triamterene, The risk or severity of hyperkalemia can be increased when Triamterene is combined with Eplerenone.]
[N05CD05, triazolam, Eplerenone may increase the excretion rate of Triazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Eplerenone can be increased when used in combination with Trichlormethiazide.]
[A16AX12, trientine, Eplerenone may increase the excretion rate of Triethylenetetramine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AB06, trifluoperazine, Trifluoperazine may decrease the antihypertensive activities of Eplerenone.]
[S01AD02, trifluridine, Eplerenone may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA07, mometasone, The metabolism of Eplerenone can be increased when combined with Mometasone.]
[A03AA05, trimebutine, Eplerenone may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01ED04, metipranolol, Eplerenone may increase the hypotensive activities of Metipranolol.]
[N03AC02, trimethadione, The risk or severity of hyperkalemia can be increased when Trimethadione is combined with Eplerenone.]
[C02BA01, trimethaphan, Eplerenone may increase the hypotensive activities of Trimethaphan.]
[J01EA01, trimethoprim, Eplerenone may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA06, trimipramine, Trimipramine may decrease the antihypertensive activities of Eplerenone.]
[J01FA08, troleandomycin, The metabolism of Eplerenone can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, Vilazodone may decrease the antihypertensive activities of Eplerenone.]
[C09CA09, azilsartan medoxomil, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Azilsartan medoxomil.]
[R03DX07, roflumilast, Eplerenone may increase the excretion rate of Roflumilast which could result in a lower serum level and potentially a reduction in efficacy.]
[L01FX04, ipilimumab, Eplerenone may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy.]
[R02AA14, oxyquinoline, Eplerenone may increase the excretion rate of Oxyquinoline which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH05, linagliptin, The metabolism of Eplerenone can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Eplerenone can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Eplerenone can be decreased when combined with Telaprevir.]
[S01AA28, vancomycin, Eplerenone may increase the excretion rate of Vancomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX21, ezogabine, Eplerenone may increase the excretion rate of Ezogabine which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AF01, rivaroxaban, Eplerenone may increase the excretion rate of Rivaroxaban which could result in a lower serum level and potentially a reduction in efficacy.]
[R03AC18, indacaterol, Indacaterol may decrease the antihypertensive activities of Eplerenone.]
[B01AC24, ticagrelor, The metabolism of Ticagrelor can be decreased when combined with Eplerenone.]
[C08DA01, verapamil, The metabolism of Eplerenone can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Eplerenone can be decreased when combined with Viloxazine.]
[C04AX07, vincamine, Eplerenone may increase the hypotensive activities of Vincamine.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Eplerenone.]
[B03BA01, vitamin B12, Eplerenone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AA03, warfarin, Eplerenone may increase the excretion rate of Warfarin which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AX15, xenon, Xenon may decrease the antihypertensive activities of Eplerenone.]
[C03BA10, xipamide, Eplerenone may increase the hypotensive activities of Xipamide.]
[N05AF05, zuclopenthixol, Zuclopenthixol may decrease the antihypertensive activities of Eplerenone.]
[J05AE02, indinavir, The metabolism of Eplerenone can be decreased when combined with Indinavir.]
[M05BA05, tiludronic acid, Eplerenone may increase the excretion rate of Tiludronic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[B06AC02, icatibant, Eplerenone may increase the excretion rate of Icatibant which could result in a lower serum level and potentially a reduction in efficacy.]
[L01ED01, crizotinib, The metabolism of Eplerenone can be decreased when combined with Crizotinib.]
[A02BC04, rabeprazole, Eplerenone may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AE04, ziprasidone, The metabolism of Eplerenone can be decreased when combined with Ziprasidone.]
[G03AC10, drospirenone, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Drospirenone.]
[V03AC02, deferiprone, Eplerenone may increase the excretion rate of Deferiprone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the excretion rate of Eplerenone which could result in a higher serum level.]
[L01EJ01, ruxolitinib, Eplerenone may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD07, tolterodine, Eplerenone may increase the excretion rate of Tolterodine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DH04, doripenem, Eplerenone may increase the excretion rate of Doripenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB03, atenolol, Atenolol may increase the hypotensive activities of Eplerenone.]
[L01FA01, rituximab, Eplerenone may increase the hypotensive activities of Rituximab.]
[J02AC03, voriconazole, The metabolism of Eplerenone can be decreased when combined with Voriconazole.]
[S01FA01, atropine, Atropine may decrease the antihypertensive activities of Eplerenone.]
[M01CB03, auranofin, Eplerenone may increase the excretion rate of Auranofin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Eplerenone.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be decreased when combined with Eplerenone.]
[H02AB11, prednylidene, The metabolism of Eplerenone can be increased when combined with Prednylidene.]
[B03XA04, peginesatide, Eplerenone may increase the excretion rate of Peginesatide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC07, azacitidine, Eplerenone may increase the excretion rate of Azacitidine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX01, azathioprine, Eplerenone may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC05, gemcitabine, Eplerenone may increase the excretion rate of Gemcitabine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DF01, aztreonam, Eplerenone may increase the excretion rate of Aztreonam which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Eplerenone.]
[M03BX01, baclofen, The risk or severity of adverse effects can be increased when Baclofen is combined with Eplerenone.]
[A08AA11, lorcaserin, Eplerenone may increase the excretion rate of Lorcaserin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD12, mirabegron, Eplerenone may increase the excretion rate of Mirabegron which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AX03, cobicistat, The metabolism of Eplerenone can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Eplerenone can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Eplerenone can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The risk or severity of adverse effects can be increased when Eplerenone is combined with Linaclotide.]
[C01CA18, octopamine, Octopamine may decrease the antihypertensive activities of Eplerenone.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Eplerenone.]
[C01AA01, acetyldigitoxin, Eplerenone may decrease the excretion rate of Acetyldigitoxin which could result in a higher serum level.]
[D02BA02, octinoxate, Eplerenone may increase the excretion rate of Octinoxate which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE04, nelfinavir, The metabolism of Eplerenone can be decreased when combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the antihypertensive activities of Eplerenone.]
[N04BD02, rasagiline, Rasagiline may increase the hypotensive activities of Eplerenone.]
[C08CA13, lercanidipine, Lercanidipine may increase the hypotensive activities of Eplerenone.]
[N03AX22, perampanel, The metabolism of Perampanel can be decreased when combined with Eplerenone.]
[N02CC03, zolmitriptan, Zolmitriptan may decrease the antihypertensive activities of Eplerenone.]
[V09IX04, fluorodeoxyglucose F18, Eplerenone may increase the excretion rate of Fludeoxyglucose (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AA01, ethyl ether, Diethyl ether may decrease the antihypertensive activities of Eplerenone.]
[G04BE03, sildenafil, Sildenafil may increase the antihypertensive activities of Eplerenone.]
[V08CA11, gadofosveset, Eplerenone may increase the excretion rate of Gadofosveset trisodium which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Eplerenone.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Eplerenone.]
[A16AX08, teduglutide, Eplerenone may increase the excretion rate of Teduglutide which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AX11, bencyclane, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Bencyclane.]
[A10BH04, alogliptin, Eplerenone may increase the excretion rate of Alogliptin which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX09, glycerol phenylbutyrate, Eplerenone may increase the excretion rate of Glycerol phenylbutyrate which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Eplerenone can be increased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, Eplerenone may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA10, benorilate, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Benorilate is combined with Eplerenone.]
[A10BK02, canagliflozin, Eplerenone may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AX06, tegaserod, The risk or severity of adverse effects can be increased when Eplerenone is combined with Tegaserod.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Eplerenone.]
[L03AA12, ancestim, Eplerenone may increase the excretion rate of Ancestim which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH01, celecoxib, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Celecoxib is combined with Eplerenone.]
[N02CC02, naratriptan, Naratriptan may decrease the antihypertensive activities of Eplerenone.]
[N04AC01, benztropine, Eplerenone may increase the excretion rate of Benzatropine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EC02, dabrafenib, The serum concentration of Eplerenone can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Benzydamine is combined with Eplerenone.]
[L01EE01, trametinib, Eplerenone may increase the excretion rate of Trametinib which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AX05, florbetapir F-18, Eplerenone may increase the excretion rate of Florbetapir (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX28, levomilnacipran, Eplerenone may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[C08EA02, bepridil, Eplerenone may increase the hypotensive activities of Bepridil.]
[C02KX05, riociguat, Eplerenone may increase the hypotensive activities of Riociguat.]
[A10BJ03, lixisenatide, Eplerenone may increase the excretion rate of Lixisenatide which could result in a lower serum level and potentially a reduction in efficacy.]
[C02KX04, macitentan, Eplerenone may increase the excretion rate of Macitentan which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Eplerenone.]
[N06AX26, vortioxetine, Eplerenone may increase the excretion rate of Vortioxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[G03AC08, etonogestrel, Eplerenone may increase the excretion rate of Etonogestrel which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AP05, simeprevir, The metabolism of Eplerenone can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Eplerenone may increase the excretion rate of Sofosbuvir which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BK01, dapagliflozin, The risk or severity of adverse effects can be increased when Eplerenone is combined with Dapagliflozin.]
[C01CA27, droxidopa, Eplerenone may increase the excretion rate of Droxidopa which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB04, acebutolol, Eplerenone may increase the hypotensive activities of Acebutolol.]
[N05CH03, tasimelteon, Eplerenone may increase the excretion rate of Tasimelteon which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AA07, metreleptin, The metabolism of Eplerenone can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Eplerenone can be increased when combined with Apremilast.]
[L02BG02, formestane, Eplerenone may increase the excretion rate of Formestane which could result in a lower serum level and potentially a reduction in efficacy.]
[S03BA03, betamethasone, The metabolism of Eplerenone can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, Betaxolol may increase the hypotensive activities of Eplerenone.]
[V03AB34, fomepizole, Eplerenone may increase the excretion rate of Fomepizole which could result in a lower serum level and potentially a reduction in efficacy.]
[C02CC01, bethanidine, Bethanidine may decrease the antihypertensive activities of Eplerenone.]
[L04AC11, siltuximab, The metabolism of Eplerenone can be increased when combined with Siltuximab.]
[A10BK03, empagliflozin, Empagliflozin may increase the diuretic activities of Eplerenone.]
[R03AC19, olodaterol, Olodaterol may decrease the antihypertensive activities of Eplerenone.]
[V08AA01, diatrizoic acid, Eplerenone may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EE02, unoprostone, Eplerenone may increase the hypotensive activities of Unoprostone.]
[V08AA04, iothalamic acid, Eplerenone may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AA04, acepromazine, Acepromazine may decrease the antihypertensive activities of Eplerenone.]
[A06AB04, phenolphthalein, The risk or severity of adverse effects can be increased when Eplerenone is combined with Phenolphthalein.]
[A06AH03, naloxegol, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Naloxegol.]
[A06AG02, bisacodyl, The risk or severity of adverse effects can be increased when Eplerenone is combined with Bisacodyl.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Eplerenone.]
[B01AF03, edoxaban, Eplerenone may increase the excretion rate of Edoxaban which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX11, mirtazapine, Mirtazapine may decrease the antihypertensive activities of Eplerenone.]
[L04AC10, secukinumab, The metabolism of Eplerenone can be increased when combined with Secukinumab.]
[J05AP07, daclatasvir, The metabolism of Daclatasvir can be decreased when combined with Eplerenone.]
[N02BE01, acetaminophen, Eplerenone may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DC01, bleomycin, Eplerenone may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Eplerenone.]
[A07DA06, eluxadoline, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Eluxadoline.]
[N05AX16, brexpiprazole, Brexpiprazole may decrease the antihypertensive activities of Eplerenone.]
[G02CX02, flibanserin, Flibanserin may decrease the antihypertensive activities of Eplerenone.]
[A06AD03, magnesium peroxide, The risk or severity of adverse effects can be increased when Eplerenone is combined with Magnesium peroxide.]
[N05AX15, cariprazine, Cariprazine may decrease the antihypertensive activities of Eplerenone.]
[M02AA25, aceclofenac, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aceclofenac is combined with Eplerenone.]
[M01AB11, acemetacin, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Acemetacin.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Eplerenone.]
[V03AB37, idarucizumab, Eplerenone may increase the excretion rate of Idarucizumab which could result in a lower serum level and potentially a reduction in efficacy.]
[J02AC05, isavuconazole, The metabolism of Eplerenone can be decreased when combined with Isavuconazole.]
[L01XG03, ixazomib, Eplerenone may increase the excretion rate of Ixazomib which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC27, selexipag, Eplerenone may increase the hypotensive activities of Selexipag.]
[G04CA01, alfuzosin, Alfuzosin may increase the hypotensive activities of Eplerenone.]
[M04AB05, lesinurad, Eplerenone may increase the excretion rate of Lesinurad which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AP10, elbasvir, The metabolism of Elbasvir can be decreased when combined with Eplerenone.]
[M01AE16, alminoprofen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Alminoprofen is combined with Eplerenone.]
[N03AX23, brivaracetam, Eplerenone may increase the excretion rate of Brivaracetam which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX52, venetoclax, The metabolism of Eplerenone can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, Eplerenone may increase the excretion rate of Bromazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC01, bromocriptine, Bromocriptine may decrease the antihypertensive activities of Eplerenone.]
[A02AD05, aluminum magnesium silicate, Eplerenone may increase the excretion rate of Almasilate which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA19, amineptin, Amineptine may decrease the antihypertensive activities of Eplerenone.]
[C08CA01, amlodipine, Amlodipine may increase the hypotensive activities of Eplerenone.]
[C03CA02, bumetanide, Eplerenone may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Eplerenone.]
[C07AA19, bupranolol, Eplerenone may increase the hypotensive activities of Bupranolol.]
[N07BC01, buprenorphine, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Buprenorphine.]
[N05BE01, buspirone, Eplerenone may increase the excretion rate of Buspirone which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX27, arsenic trioxide, Eplerenone may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Eplerenone.]
[M02AA03, clofezone, Eplerenone may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AF01, butorphanol, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Butorphanol.]
[S01GX07, azelastine, The metabolism of Azelastine can be decreased when combined with Eplerenone.]
[L01XK03, rucaparib, The metabolism of Eplerenone can be decreased when combined with Rucaparib.]
[A06AX07, plecanatide, The risk or severity of adverse effects can be increased when Eplerenone is combined with Plecanatide.]
[L01EF02, ribociclib, The metabolism of Eplerenone can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Balsalazide is combined with Eplerenone.]
[R03CC12, bambuterol, Bambuterol may decrease the antihypertensive activities of Eplerenone.]
[A06AH05, naldemedine, Eplerenone may increase the excretion rate of Naldemedine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX16, deutetrabenazine, Eplerenone may increase the excretion rate of Deutetrabenazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BF02, pregabalin, Eplerenone may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA07, benazepril, Eplerenone may increase the hyperkalemic activities of Benazepril.]
[P01CA02, benznidazole, Eplerenone may increase the excretion rate of Benznidazole which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XX08, linezolid, Linezolid may increase the hypotensive activities of Eplerenone.]
[J05AF06, abacavir, Eplerenone may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE09, tipranavir, The metabolism of Eplerenone can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, Eplerenone may increase the excretion rate of Valbenazine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AB02, infliximab, The metabolism of Eplerenone can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Eplerenone can be decreased when combined with Midostaurin.]
[N04BD03, safinamide, Safinamide may increase the hypotensive activities of Eplerenone.]
[J01MA23, delafloxacin, Eplerenone may increase the excretion rate of Delafloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC06, capecitabine, Eplerenone may increase the excretion rate of Capecitabine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Eplerenone.]
[C07AB07, bisoprolol, Eplerenone may increase the excretion rate of Bisoprolol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03AC17, bitolterol, Bitolterol may decrease the antihypertensive activities of Eplerenone.]
[J05AG03, efavirenz, The metabolism of Eplerenone can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Bopindolol.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Eplerenone is combined with Nesiritide.]
[C03DA03, canrenone, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Canrenone.]
[R03BA02, budesonide, Eplerenone may increase the excretion rate of Budesonide which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AX20, buflomedil, Buflomedil may decrease the antihypertensive activities of Eplerenone.]
[M01AB07, bumadizone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Bumadizone is combined with Eplerenone.]
[L01EL02, acalabrutinib, The metabolism of Eplerenone can be decreased when combined with Acalabrutinib.]
[J05AX18, letermovir, The metabolism of Eplerenone can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, Butriptyline may decrease the antihypertensive activities of Eplerenone.]
[C01AA02, acetyldigoxins, Eplerenone may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level.]
[R06AX18, acrivastine, Eplerenone may increase the excretion rate of Acrivastine which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA01, captopril, Eplerenone may increase the hyperkalemic activities of Captopril.]
[L02BB05, apalutamide, The metabolism of Eplerenone can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Carbamazepine can be decreased when combined with Eplerenone.]
[A06AC08, calcium polycarbophil, The risk or severity of adverse effects can be increased when Eplerenone is combined with Calcium polycarbophil.]
[C07AG02, carvedilol, Eplerenone may increase the hypotensive activities of Carvedilol.]
[B02BX09, fostamatinib, Fostamatinib may increase the antihypertensive activities of Eplerenone.]
[N03AX24, cannabidiol, The metabolism of Eplerenone can be decreased when combined with Cannabidiol.]
[L04AA37, baricitinib, Eplerenone may increase the excretion rate of Baricitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD14, ceftibuten, Eplerenone may increase the excretion rate of Ceftibuten which could result in a lower serum level and potentially a reduction in efficacy.]
[J01GB14, plazomicin, Eplerenone may increase the excretion rate of Plazomicin which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB08, celiprolol, Eplerenone may increase the hypotensive activities of Celiprolol.]
[L01XX62, ivosidenib, The metabolism of Eplerenone can be increased when combined with Ivosidenib.]
[A16AX14, migalastat, Eplerenone may increase the excretion rate of Migalastat which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX17, stiripentol, The metabolism of Eplerenone can be decreased when combined with Stiripentol.]
[J05AG06, doravirine, The metabolism of Doravirine can be decreased when combined with Eplerenone.]
[S01GX12, cetirizine, Eplerenone may increase the excretion rate of Cetirizine which could result in a lower serum level and potentially a reduction in efficacy.]
[D08AE05, chloroxylenol, Eplerenone may increase the excretion rate of Chloroxylenol which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC05, lornoxicam, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lornoxicam is combined with Eplerenone.]
[L01ED05, lorlatinib, The metabolism of Lorlatinib can be decreased when combined with Eplerenone.]
[L04AA39, emapalumab, The metabolism of Eplerenone can be increased when combined with Emapalumab.]
[L01AD01, carmustine, Eplerenone may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AX05, prucalopride, The risk or severity of adverse effects can be increased when Eplerenone is combined with Prucalopride.]
[C09AA08, cilazapril, Eplerenone may increase the hyperkalemic activities of Cilazapril.]
[B01AC23, cilostazol, Eplerenone may increase the excretion rate of Cilostazol which could result in a lower serum level and potentially a reduction in efficacy.]
[A03FA08, cinitapride, Cinitapride may decrease the antihypertensive activities of Eplerenone.]
[S01ED05, carteolol, Carteolol may increase the hypotensive activities of Eplerenone.]
[L04AA42, siponimod, Siponimod may decrease the antihypertensive activities of Eplerenone.]
[J01FA09, clarithromycin, The metabolism of Eplerenone can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, Eplerenone may increase the excretion rate of Solriamfetol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA09, clobazam, Eplerenone may increase the excretion rate of Clobazam which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AB14, cloprednol, The metabolism of Eplerenone can be increased when combined with Cloprednol.]
[A06AB05, castor oil, The risk or severity of adverse effects can be increased when Eplerenone is combined with Castor oil.]
[C09CA06, candesartan, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Eplerenone can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Eplerenone can be increased when combined with Cortivazol.]
[J01DC04, cefaclor, Eplerenone may increase the excretion rate of Cefaclor which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB05, cefadroxil, Eplerenone may increase the excretion rate of Cefadroxil which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DC05, cefotetan, Eplerenone may increase the excretion rate of Cefotetan which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD02, ceftazidime, Eplerenone may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BX03, cicletanine, Eplerenone may increase the hypotensive activities of Cicletanine.]
[J01DD04, ceftriaxone, Eplerenone may increase the excretion rate of Ceftriaxone which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX11, pitolisant, The serum concentration of Eplerenone can be decreased when it is combined with Pitolisant.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Eplerenone.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Eplerenone can be increased when used in combination with Cyclothiazide.]
[G04BE04, yohimbine, Yohimbine may decrease the antihypertensive activities of Eplerenone.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Eplerenone.]
[A06AB03, danthron, The risk or severity of adverse effects can be increased when Eplerenone is combined with Dantron.]
[J01XX09, daptomycin, Eplerenone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB01, cephalexin, Eplerenone may increase the excretion rate of Cephalexin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB09, cephradine, Eplerenone may increase the excretion rate of Cefradine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Eplerenone.]
[N03AX25, cenobamate, The serum concentration of Eplerenone can be decreased when it is combined with Cenobamate.]
[M09AX08, golodirsen, Eplerenone may increase the excretion rate of Golodirsen which could result in a lower serum level and potentially a reduction in efficacy.]
[S01XA12, dexpanthenol, Eplerenone may increase the excretion rate of Dexpanthenol which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX03, dezocine, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Dezocine.]
[N05CM21, lemborexant, The metabolism of Lemborexant can be decreased when combined with Eplerenone.]
[H02CA02, osilodrostat, The metabolism of Eplerenone can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Eplerenone can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, Frovatriptan may decrease the antihypertensive activities of Eplerenone.]
[G04CB02, dutasteride, Dutasteride may decrease the antihypertensive activities of Eplerenone.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Eplerenone.]
[R02AA03, dichlorobenzyl alcohol, Eplerenone may increase the excretion rate of Dichlorobenzyl alcohol which could result in a lower serum level and potentially a reduction in efficacy.]
[G03DB08, dienogest, Eplerenone may increase the excretion rate of Dienogest which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AA08, dihydrocodeine, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Dihydrocodeine.]
[N02CC06, eletriptan, Eletriptan may decrease the antihypertensive activities of Eplerenone.]
[M01AH02, rofecoxib, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Rofecoxib is combined with Eplerenone.]
[C08CA16, clevidipine, Eplerenone may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BD07, dronedarone, The metabolism of Eplerenone can be decreased when combined with Dronedarone.]
[S03AA08, chloramphenicol, The metabolism of Eplerenone can be decreased when combined with Chloramphenicol.]
[C02AA06, methoserpidine, Eplerenone may increase the hypotensive activities of Methoserpidine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Eplerenone.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Eplerenone is combined with Opicapone.]
[C01CA14, dopexamine, Dopexamine may decrease the antihypertensive activities of Eplerenone.]
[D07XB03, fluprednidene, The metabolism of Eplerenone can be increased when combined with Fluprednidene.]
[M01AC04, droxicam, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Droxicam is combined with Eplerenone.]
[V08CA05, mangafodipir, Eplerenone may increase the excretion rate of Mangafodipir which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX22, selpercatinib, Selpercatinib may decrease the antihypertensive activities of Eplerenone.]
[M02AA27, dexketoprofen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Dexketoprofen is combined with Eplerenone.]
[C08CA17, levamlodipine, Eplerenone may increase the hypotensive activities of Levamlodipine.]
[L04AC19, satralizumab, The serum concentration of Eplerenone can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Oliceridine.]
[P01BA01, chloroquine, Eplerenone may increase the excretion rate of Chloroquine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX23, pralsetinib, The metabolism of Eplerenone can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Eplerenone can be increased when used in combination with Chlorothiazide.]
[R06AB04, chlorpheniramine, The metabolism of Chlorpheniramine can be decreased when combined with Eplerenone.]
[N05AA01, chlorpromazine, Eplerenone may increase the excretion rate of Chlorpromazine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BB02, chlorpropamide, Eplerenone may increase the excretion rate of Chlorpropamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the hypotensive activities of Eplerenone.]
[M03BB03, chlorzoxazone, Eplerenone may increase the excretion rate of Chlorzoxazone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA07, ethenzamide, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ethenzamide is combined with Eplerenone.]
[N02BA03, choline salicylate, Eplerenone may increase the excretion rate of Choline salicylate which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BX18, vinpocetine, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Vinpocetine.]
[M01AB08, etodolac, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etodolac is combined with Eplerenone.]
[M02AA06, etofenamate, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etofenamate is combined with Eplerenone.]
[B06AC06, berotralstat, The metabolism of Eplerenone can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Eplerenone can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The metabolism of Relugolix can be decreased when combined with Eplerenone.]
[M01AX25, chondroitin sulfates, Eplerenone may increase the excretion rate of Chondroitin sulfate which could result in a lower serum level and potentially a reduction in efficacy.]
[L01FX21, naxitamab, Naxitamab may decrease the antihypertensive activities of Eplerenone.]
[P03AX07, abametapir, The serum concentration of Eplerenone can be increased when it is combined with Abametapir.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Eplerenone is combined with Vericiguat.]
[M01AE05, fenbufen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fenbufen is combined with Eplerenone.]
[C01CA19, fenoldopam, Eplerenone may increase the excretion rate of Fenoldopam which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BA08, fenozolone, Fenozolone may decrease the antihypertensive activities of Eplerenone.]
[G04CB01, finasteride, Finasteride may decrease the antihypertensive activities of Eplerenone.]
[J01DD15, cefdinir, Eplerenone may increase the excretion rate of Cefdinir which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG07, flupirtine, Eplerenone may increase the excretion rate of Flupirtine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC15, formoterol, Formoterol may decrease the antihypertensive activities of Eplerenone.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Eplerenone.]
[L04AA50, ponesimod, The metabolism of Ponesimod can be decreased when combined with Eplerenone.]
[N01AB05, trichloroethylene, Trichloroethylene may decrease the antihypertensive activities of Eplerenone.]
[H04AA02, dasiglucagon, Eplerenone may increase the hypotensive activities of Dasiglucagon.]
[A02BA01, cimetidine, Eplerenone may increase the excretion rate of Cimetidine which could result in a lower serum level and potentially a reduction in efficacy.]
[V08CA04, gadoteridol, Eplerenone may increase the excretion rate of Gadoteridol which could result in a lower serum level and potentially a reduction in efficacy.]
[N07CA02, cinnarizine, The risk or severity of hyperkalemia can be increased when Cinnarizine is combined with Eplerenone.]
[L01XX73, sotorasib, The serum concentration of Eplerenone can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Eplerenone can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, Eplerenone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[C03DA05, finerenone, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Finerenone.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Eplerenone.]
[L01EB10, mobocertinib, The metabolism of Mobocertinib can be decreased when combined with Eplerenone.]
[V09AB03, ioflupane I-123, Eplerenone may increase the excretion rate of Ioflupane I-123 which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AA01, technetium Tc 99m exametazime, Eplerenone may increase the excretion rate of Technetium Tc-99m exametazime which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AX06, florbetaben f-18, Eplerenone may increase the excretion rate of Florbetaben (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC13, clenbuterol, Clenbuterol may decrease the antihypertensive activities of Eplerenone.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be decreased when combined with Eplerenone.]
[N06AX25, St. John's wort extract, The metabolism of Eplerenone can be increased when combined with St. John's Wort.]
[J04BA01, clofazimine, The metabolism of Eplerenone can be decreased when combined with Clofazimine.]
[N01BB10, levobupivacaine, Eplerenone may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA04, clomipramine, Eplerenone may increase the excretion rate of Clomipramine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AE01, clonazepam, Eplerenone may increase the excretion rate of Clonazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EA04, clonidine, The risk or severity of hypotension can be increased when Clonidine is combined with Eplerenone.]
[C01EB24, mavacamten, The serum concentration of Eplerenone can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Eplerenone may increase the excretion rate of Oseltamivir which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be decreased when combined with Eplerenone.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be decreased when combined with Eplerenone.]
[L01XX77, adagrasib, The serum concentration of Eplerenone can be increased when it is combined with Adagrasib.]
[N05AH02, clozapine, The metabolism of Eplerenone can be decreased when combined with Clozapine.]
[H01AC08, somatrogon, The metabolism of Eplerenone can be increased when combined with Somatrogon.]
[C02KB01, metyrosine, Eplerenone may increase the hypotensive activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Eplerenone can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Proquazone is combined with Eplerenone.]
[R05DA04, codeine, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Codeine.]
[M04AC01, colchicine, Eplerenone may increase the excretion rate of Colchicine which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AB07, desflurane, Desflurane may decrease the antihypertensive activities of Eplerenone.]
[A04AA03, tropisetron, Eplerenone may increase the excretion rate of Tropisetron which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AX28, ifenprodil, Ifenprodil may decrease the antihypertensive activities of Eplerenone.]
[A10BX03, nateglinide, Eplerenone may increase the excretion rate of Nateglinide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Imidazole salicylate is combined with Eplerenone.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Eplerenone.]
[J01FA15, telithromycin, The metabolism of Eplerenone can be decreased when combined with Telithromycin.]
[B01AC10, indobufen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indobufen is combined with Eplerenone.]
[J05AB14, valganciclovir, Eplerenone may increase the excretion rate of Valganciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C05BB03, invert sugar, Eplerenone may increase the excretion rate of Invert sugar which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB09, iodixanol, Eplerenone may increase the excretion rate of Iodixanol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB05, iopromide, Eplerenone may increase the excretion rate of Iopromide which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB07, ioversol, Eplerenone may increase the excretion rate of Ioversol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB12, ioxilan, Eplerenone may increase the excretion rate of Ioxilan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH03, valdecoxib, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Valdecoxib is combined with Eplerenone.]
[C01AA06, lanatoside C, Eplerenone may decrease the excretion rate of Lanatoside C which could result in a higher serum level.]
[A03AX10, isometheptene, Isometheptene may decrease the antihypertensive activities of Eplerenone.]
[N02CC05, almotriptan, Eplerenone may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH04, parecoxib, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Parecoxib is combined with Eplerenone.]
[J02AC02, itraconazole, The metabolism of Eplerenone can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Bemiparin.]
[S01AD03, acyclovir, Eplerenone may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA10, ketazolam, Eplerenone may increase the excretion rate of Ketazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AA06, kebuzone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Kebuzone is combined with Eplerenone.]
[L01EA01, imatinib, The metabolism of Eplerenone can be decreased when combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Eplerenone can be decreased when combined with Posaconazole.]
[S01EE04, travoprost, Travoprost may increase the hypotensive activities of Eplerenone.]
[S01EE03, bimatoprost, Eplerenone may increase the hypotensive activities of Bimatoprost.]
[C08CA09, lacidipine, Eplerenone may increase the hypotensive activities of Lacidipine.]
[A06AD12, lactitol, The risk or severity of adverse effects can be increased when Eplerenone is combined with Lactitol.]
[N03AX09, lamotrigine, Eplerenone may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BA03, cortisone, The metabolism of Eplerenone can be increased when combined with Cortisone.]
[N07BC04, lofexidine, Eplerenone may increase the excretion rate of Lofexidine which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AB09, lonazolac, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lonazolac is combined with Eplerenone.]
[M02AA31, loxoprofen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Loxoprofen is combined with Eplerenone.]
[C09AA03, lisinopril, Eplerenone may increase the hyperkalemic activities of Lisinopril.]
[A06AD01, magnesium carbonate, The risk or severity of adverse effects can be increased when Eplerenone is combined with Magnesium carbonate.]
[C08CA11, manidipine, Eplerenone may increase the hypotensive activities of Manidipine.]
[A08AA09, mefenorex, Mefenorex may decrease the antihypertensive activities of Eplerenone.]
[C07AA14, mepindolol, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Mepindolol.]
[H02AB15, meprednisone, The metabolism of Eplerenone can be increased when combined with Meprednisone.]
[J01DH02, meropenem, Eplerenone may increase the excretion rate of Meropenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AX01, cyclandelate, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Cyclandelate.]
[R03CB02, methoxyphenamine, Methoxyphenamine may decrease the antihypertensive activities of Eplerenone.]
[S01AA13, fusidic acid, The metabolism of Eplerenone can be decreased when combined with Fusidic acid.]
[S02BA08, fluocinolone acetonide, Eplerenone may increase the excretion rate of Fluocinolone acetonide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AG01, mefenamic acid, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mefenamic acid is combined with Eplerenone.]
[N05AD03, metylperon, Eplerenone may increase the excretion rate of Melperone which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Eplerenone can be increased when used in combination with Cyclopenthiazide.]
[J05AF07, tenofovir disoproxil, Eplerenone may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Eplerenone.]
[N06AX07, minaprine, Minaprine may increase the hypotensive activities of Eplerenone.]
[S01XA18, cyclosporine, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the hypotensive activities of Eplerenone.]
[N06BA07, modafinil, The metabolism of Eplerenone can be increased when combined with Modafinil.]
[C09AA13, moexipril, Eplerenone may increase the hyperkalemic activities of Moexipril.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be decreased when combined with Eplerenone.]
[M02AA02, mofebutazone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mofebutazone is combined with Eplerenone.]
[M01AX22, morniflumate, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Morniflumate is combined with Eplerenone.]
[C03XA02, conivaptan, The metabolism of Eplerenone can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, Moxonidine may decrease the antihypertensive activities of Eplerenone.]
[G04BE09, vardenafil, Vardenafil may increase the antihypertensive activities of Eplerenone.]
[M01AH05, etoricoxib, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etoricoxib is combined with Eplerenone.]
[L01AX04, dacarbazine, Eplerenone may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.]
[G03XA01, danazol, The metabolism of Eplerenone can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Dantrolene.]
[J04BA02, dapsone, The metabolism of Eplerenone can be decreased when combined with Dapsone.]
[L01DB02, daunorubicin, The metabolism of Eplerenone can be increased when combined with Daunorubicin.]
[C02CC04, debrisoquin, Eplerenone may increase the hypotensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Nabilone is combined with Eplerenone.]
[M01AX01, nabumetone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nabumetone is combined with Eplerenone.]
[N07BB05, nalmefene, Eplerenone may increase the excretion rate of Nalmefene which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA15, potassium lactate, The risk or severity of hyperkalemia can be increased when Potassium lactate is combined with Eplerenone.]
[C07AB12, nebivolol, Eplerenone may increase the hypotensive activities of Nebivolol.]
[S01GX04, nedocromil, Eplerenone may increase the excretion rate of Nedocromil which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX06, nefazodone, The metabolism of Eplerenone can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Eplerenone.]
[L02BB02, nilutamide, Eplerenone may increase the excretion rate of Nilutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA23, theodrenaline, The risk or severity of Cardiac Arrhythmia can be increased when Theodrenaline is combined with Eplerenone.]
[C01CA05, norfenefrine, Norfenefrine may decrease the antihypertensive activities of Eplerenone.]
[R05DA06, normethadone, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Normethadone.]
[B01AX05, fondaparinux, Eplerenone may increase the excretion rate of Fondaparinux which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD08, solifenacin, Solifenacin may decrease the antihypertensive activities of Eplerenone.]
[A07EC03, olsalazine, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olsalazine is combined with Eplerenone.]
[N06AA01, desipramine, Eplerenone may increase the excretion rate of Desipramine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01AA07, deslanoside, Eplerenone may decrease the excretion rate of Deslanoside which could result in a higher serum level.]
[H01BA02, desmopressin, Eplerenone may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DH03, ertapenem, Eplerenone may increase the excretion rate of Ertapenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C09XA02, aliskiren, Eplerenone may increase the hypotensive activities of Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Oxaprozin is combined with Eplerenone.]
[N03AF02, oxcarbazepine, The metabolism of Eplerenone can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Eplerenone can be increased when combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Oxybutynin can be decreased when combined with Eplerenone.]
[L04AB04, adalimumab, The metabolism of Eplerenone can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Eplerenone can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, Eplerenone may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[R05DA09, dextromethorphan, The metabolism of Eplerenone can be decreased when combined with Dextromethorphan.]
[N02AC01, dextromoramide, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Dextromoramide.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be decreased when combined with Eplerenone.]
[N07BC06, heroin, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Diamorphine.]
[C01DA05, pentaerythritol tetranitrate, Eplerenone may increase the excretion rate of Pentaerythritol tetranitrate which could result in a lower serum level and potentially a reduction in efficacy.]
[P03AC04, permethrin, Eplerenone may increase the excretion rate of Permethrin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA01, diazepam, Eplerenone may increase the excretion rate of Diazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AH01, diazoxide, Diazoxide may increase the hypotensive activities of Eplerenone.]
[N06AA08, dibenzepin, Dibenzepin may decrease the antihypertensive activities of Eplerenone.]
[R05DA08, pholcodine, Eplerenone may increase the excretion rate of Pholcodine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Eplerenone is combined with Diclofenamide.]
[S01BC03, diclofenac, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Diclofenac is combined with Eplerenone.]
[A03AA07, dicyclomine, Eplerenone may increase the excretion rate of Dicyclomine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF02, didanosine, Eplerenone may increase the excretion rate of Didanosine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DG01, pinacidil, Eplerenone may increase the hypotensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Pinaverium.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Eplerenone is combined with Pipamperone.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Eplerenone.]
[R03CC07, pirbuterol, Pirbuterol may decrease the antihypertensive activities of Eplerenone.]
[A08AA03, diethylpropion, Diethylpropion may decrease the antihypertensive activities of Eplerenone.]
[C08CA03, isradipine, The metabolism of Eplerenone can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, Eplerenone may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA11, diflunisal, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Diflunisal is combined with Eplerenone.]
[C01AA04, digitoxin, Eplerenone may decrease the excretion rate of Digitoxin which could result in a higher serum level.]
[C01AA05, digoxin, Eplerenone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02DB01, dihydralazine, Eplerenone may increase the hypotensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, Dihydroergocristine may decrease the antihypertensive activities of Eplerenone.]
[N02CA01, dihydroergotamine, Dihydroergotamine may decrease the antihypertensive activities of Eplerenone.]
[N02AA03, hydromorphone, Eplerenone may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX04, lenalidomide, Eplerenone may increase the excretion rate of Lenalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE08, atazanavir, The metabolism of Eplerenone can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, Treprostinil may increase the hypotensive activities of Eplerenone.]
[H03BC01, potassium perchlorate, The risk or severity of hyperkalemia can be increased when Potassium perchlorate is combined with Eplerenone.]
[V03AB04, pralidoxime, Eplerenone may increase the excretion rate of Pralidoxime which could result in a lower serum level and potentially a reduction in efficacy.]
[C08DB01, diltiazem, The metabolism of Eplerenone can be decreased when combined with Diltiazem.]
[V03AB09, dimercaprol, Eplerenone may increase the excretion rate of Dimercaprol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC08, procaterol, Procaterol may decrease the antihypertensive activities of Eplerenone.]
[M02AX03, dimethyl sulfoxide, Eplerenone may increase the excretion rate of Dimethyl sulfoxide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BB04, propyphenazone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Propyphenazone is combined with Eplerenone.]
[M01AB14, proglumetacin, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Proglumetacin is combined with Eplerenone.]
[A07DA01, diphenoxylate, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Diphenoxylate.]
[C09AA06, quinapril, Eplerenone may increase the hyperkalemic activities of Quinapril.]
[B01AC07, dipyridamole, Dipyridamole may increase the antihypertensive activities of Eplerenone.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may decrease the antihypertensive activities of Eplerenone.]
[N06AA23, quinupramine, Quinupramine may decrease the antihypertensive activities of Eplerenone.]
[A03FA02, cisapride, The metabolism of Eplerenone can be decreased when combined with Cisapride.]
[C09AA05, ramipril, Eplerenone may increase the hyperkalemic activities of Ramipril.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Eplerenone.]
[R03CC14, reproterol, Reproterol may decrease the antihypertensive activities of Eplerenone.]
[S01AX06, resorcinol, Eplerenone may increase the excretion rate of Resorcinol which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BA03, disopyramide, Eplerenone may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.]
[P03AA04, disulfiram, The metabolism of Disulfiram can be decreased when combined with Eplerenone.]
[S02AA12, rifamycin SV, The metabolism of Eplerenone can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Eplerenone can be increased when combined with Rifapentine.]
[N05AX08, risperidone, Eplerenone may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, Eplerenone may increase the excretion rate of Levocetirizine which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB09, ropivacaine, Eplerenone may increase the excretion rate of Ropivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Eplerenone.]
[A04AD12, aprepitant, The metabolism of Eplerenone can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Tolvaptan.]
[G04BE08, tadalafil, Eplerenone may increase the excretion rate of Tadalafil which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC05, ketorolac, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ketorolac is combined with Eplerenone.]
[C02KX02, ambrisentan, Eplerenone may increase the hypotensive activities of Ambrisentan.]
[C01EB18, ranolazine, Eplerenone may increase the excretion rate of Ranolazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA06, salsalate, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salsalate is combined with Eplerenone.]
[R03AC12, salmeterol, Salmeterol may decrease the antihypertensive activities of Eplerenone.]
[H05BA01, salmon calcitonin, Eplerenone may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA07, dobutamine, Eplerenone may increase the excretion rate of Dobutamine which could result in a lower serum level and potentially a reduction in efficacy.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Eplerenone.]
[C01CA04, dopamine, Eplerenone may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA16, dothiepin, Dosulepin may decrease the antihypertensive activities of Eplerenone.]
[R07AB01, doxapram, Doxapram may decrease the antihypertensive activities of Eplerenone.]
[N06AA12, doxepin, Eplerenone may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AB06, sennosides, USP, The risk or severity of adverse effects can be increased when Eplerenone is combined with Sennosides.]
[J01AA02, doxycycline, Eplerenone may increase the excretion rate of Doxycycline which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AB08, sevoflurane, Sevoflurane may decrease the antihypertensive activities of Eplerenone.]
[N05AD08, droperidol, Droperidol may decrease the antihypertensive activities of Eplerenone.]
[A08AA10, sibutramine, Eplerenone may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA01, simvastatin, The metabolism of Eplerenone can be decreased when combined with Simvastatin.]
[V03AG05, sodium phosphate, Eplerenone may increase the nephrotoxic activities of Sodium phosphate, monobasic.]
[A12CA02, sodium sulfate, The risk or severity of adverse effects can be increased when Eplerenone is combined with Sodium sulfate.]
[C09AA11, spirapril, Eplerenone may increase the hyperkalemic activities of Spirapril.]
[R03DA01, dyphylline, Eplerenone may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CC01, sumatriptan, Eplerenone may increase the excretion rate of Sumatriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CX07, edrophonium, Eplerenone may increase the excretion rate of Edrophonium which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB13, talinolol, Eplerenone may increase the hypotensive activities of Talinolol.]
[L01AX03, temozolomide, Eplerenone may increase the excretion rate of Temozolomide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC02, tenoxicam, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tenoxicam is combined with Eplerenone.]
[G04CA03, terazosin, Eplerenone may increase the hypotensive activities of Terazosin.]
[G04BD05, terodiline, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Terodiline.]
[C07AA16, tertatolol, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Tertatolol.]
[S01GA02, tetrahydrozoline, Tetryzoline may decrease the antihypertensive activities of Eplerenone.]
[N06AX14, tianeptine, Tianeptine may decrease the antihypertensive activities of Eplerenone.]
[C09AA02, enalapril, Eplerenone may increase the hyperkalemic activities of Enalapril.]
[M01AG02, tolfenamic acid, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic acid is combined with Eplerenone.]
[N06AG03, toloxatone, Toloxatone may increase the hypotensive activities of Eplerenone.]
[N06BA09, atomoxetine, Eplerenone may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX11, topiramate, Eplerenone may increase the excretion rate of Topiramate which could result in a lower serum level and potentially a reduction in efficacy.]
[C03CA04, torsemide, Torasemide may increase the hypotensive activities of Eplerenone.]
[R01AA09, tramazoline, Tramazoline may decrease the antihypertensive activities of Eplerenone.]
[C09AA10, trandolapril, Eplerenone may increase the hyperkalemic activities of Trandolapril.]
[R03CC11, tulobuterol, Tulobuterol may decrease the antihypertensive activities of Eplerenone.]
[C02CA06, urapidil, Urapidil may decrease the antihypertensive activities of Eplerenone.]
[S01FB02, ephedrine, The risk or severity of Cardiac Arrhythmia can be increased when Ephedrine is combined with Eplerenone.]
[N06AX16, venlafaxine, Eplerenone may increase the excretion rate of Venlafaxine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CX07, xamoterol, Xamoterol may decrease the antihypertensive activities of Eplerenone.]
[S01GA03, xylometazoline, Xylometazoline may decrease the antihypertensive activities of Eplerenone.]
[C08CA12, mepirodipine, The metabolism of Eplerenone can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The risk or severity of Cardiac Arrhythmia can be increased when Epinephrine is combined with Eplerenone.]
[C09AA15, zofenopril, Eplerenone may increase the hyperkalemic activities of Zofenopril.]
[M01AB04, zomepirac, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Zomepirac is combined with Eplerenone.]
[N03AX15, zonisamide, Eplerenone may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Eplerenone.]
[L01XA02, carboplatin, Eplerenone may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AC02, guanfacine, Eplerenone may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC11, iloprost, Iloprost may increase the hypotensive activities of Eplerenone.]
[G02AB03, ergonovine, Ergometrine may decrease the antihypertensive activities of Eplerenone.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may decrease the antihypertensive activities of Eplerenone.]
[N02CA02, ergotamine, The metabolism of Eplerenone can be decreased when combined with Ergotamine.]
[L03AX05, pidotimod, Eplerenone may increase the excretion rate of Pidotimod which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA17, erythromycin, The metabolism of Eplerenone can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, Eplerenone may increase the excretion rate of Estazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC02, pantoprazole, Eplerenone may increase the excretion rate of Pantoprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[G03CA03, estradiol, Eplerenone may increase the excretion rate of Estradiol which could result in a lower serum level and potentially a reduction in efficacy.]
[G03CA57, estrogens, conjugated (USP), Eplerenone may increase the excretion rate of Conjugated estrogens which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AK02, ethambutol, Eplerenone may increase the excretion rate of Ethambutol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA09, fluticasone furoate, The metabolism of Eplerenone can be decreased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Eplerenone can be decreased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Eplerenone.]
[V08CA03, gadodiamide, Eplerenone may increase the excretion rate of Gadodiamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA15, gepefrine, Gepefrine may decrease the antihypertensive activities of Eplerenone.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be decreased when combined with Eplerenone.]
[V03AF05, amifostine, Eplerenone may increase the hypotensive activities of Amifostine.]
[C01BD05, ibutilide, Eplerenone may increase the excretion rate of Ibutilide which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AD01, ethosuximide, The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Eplerenone.]
[M01AC06, meloxicam, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Meloxicam.]
[S01XA06, ethylmorphine, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Ethylmorphine.]
[C01CA01, etilefrine, Etilefrine may decrease the antihypertensive activities of Eplerenone.]
[N01AX07, etomidate, Eplerenone may increase the excretion rate of Etomidate which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Eplerenone.]
[L04AD02, tacrolimus, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Tacrolimus.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Eplerenone.]
[R06AX12, terfenadine, The metabolism of Eplerenone can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Eplerenone may increase the excretion rate of Trimetrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX12, bupropion, Eplerenone may increase the excretion rate of Bupropion which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB08, fluvoxamine, The metabolism of Eplerenone can be decreased when combined with Fluvoxamine.]
[L02AE02, leuprolide, Eplerenone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01CB01, gold sodium thiomalate, Eplerenone may increase the excretion rate of Sodium aurothiomalate which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA05, dextran, Eplerenone may increase the excretion rate of Dextran which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AF02, dexrazoxane, Eplerenone may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AA01, levocarnitine, Eplerenone may increase the excretion rate of Levocarnitine which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA02, felodipine, Eplerenone may increase the hypotensive activities of Felodipine.]
[C08EA01, fendiline, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Fendiline.]
[M01AE04, fenoprofen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fenoprofen is combined with Eplerenone.]
[R03CC04, fenoterol, Fenoterol may decrease the antihypertensive activities of Eplerenone.]
[N02AB03, fentanyl, Eplerenone may increase the excretion rate of Fentanyl which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC02, albuterol, Eplerenone may increase the excretion rate of Salbutamol which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BB06, clofarabine, Eplerenone may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07AX03, cevimeline, Eplerenone may increase the excretion rate of Cevimeline which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD02, flavoxate, Eplerenone may increase the excretion rate of Flavoxate which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG04, floctafenine, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Floctafenine is combined with Eplerenone.]
[J02AC01, fluconazole, The metabolism of Eplerenone can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, Eplerenone may increase the excretion rate of Flucytosine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB25, flumazenil, Eplerenone may increase the excretion rate of Flumazenil which could result in a lower serum level and potentially a reduction in efficacy.]
[N07CA03, flunarizine, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Flunarizine.]
[D07AC08, fluocinonide, The metabolism of Eplerenone can be increased when combined with Fluocinonide.]
[N06AA14, melitracen, Melitracen may decrease the antihypertensive activities of Eplerenone.]
[H02AB03, fluocortolone, The metabolism of Eplerenone can be increased when combined with Fluocortolone.]
[V03AZ01, ethanol, Ethanol may increase the hypotensive activities of Eplerenone.]
[L01BC09, floxuridine, Eplerenone may increase the excretion rate of Floxuridine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AF01, flupenthixol, Flupentixol may decrease the antihypertensive activities of Eplerenone.]
[N05CD01, flurazepam, Eplerenone may increase the excretion rate of Flurazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC04, flurbiprofen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Flurbiprofen is combined with Eplerenone.]
[N05AG01, fluspirilene, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Fluspirilene.]
[L02BB01, flutamide, Eplerenone may increase the excretion rate of Flutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CX02, folic acid, Eplerenone may increase the excretion rate of Folic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[S02AA17, fosfomycin, Eplerenone may increase the excretion rate of Fosfomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Eplerenone.]
[N06BX17, adrafinil, Adrafinil may decrease the antihypertensive activities of Eplerenone.]
[G01AX06, furazolidone, Furazolidone may increase the hypotensive activities of Eplerenone.]
[J05AE10, darunavir, The metabolism of Eplerenone can be decreased when combined with Darunavir.]
[C03CA01, furosemide, Eplerenone may increase the excretion rate of Furosemide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, Eplerenone may increase the excretion rate of Eszopiclone which could result in a lower serum level and potentially a reduction in efficacy.]
[C08DA02, gallopamil, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Gallopamil.]
[S01AD09, ganciclovir, Eplerenone may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Eplerenone.]
[C10AB04, gemfibrozil, Eplerenone may increase the excretion rate of Gemfibrozil which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XA03, telavancin, Eplerenone may increase the excretion rate of Telavancin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Eplerenone.]
[N04BC06, cabergoline, Cabergoline may decrease the antihypertensive activities of Eplerenone.]
[N03AD03, methsuximide, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Methsuximide.]
[N01AH02, alfentanil, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Alfentanil.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Eplerenone.]
[A10BB01, glyburide, The metabolism of Glyburide can be decreased when combined with Eplerenone.]
[A10BB07, glipizide, Eplerenone may increase the excretion rate of Glipizide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CM18, dexmedetomidine, Eplerenone may increase the excretion rate of Dexmedetomidine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AX01, glycerin, The risk or severity of adverse effects can be increased when Eplerenone is combined with Glycerin.]
[C05AE01, nitroglycerin, Eplerenone may increase the hypotensive activities of Nitroglycerin.]
[C02CA04, doxazosin, Doxazosin may increase the hypotensive activities of Eplerenone.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Eplerenone.]
[C07AB09, esmolol, Esmolol may increase the hypotensive activities of Eplerenone.]
[M01CB04, aurothioglucose, Eplerenone may increase the excretion rate of Aurothioglucose which could result in a lower serum level and potentially a reduction in efficacy.]
[S01LA03, pegaptanib, Eplerenone may increase the excretion rate of Pegaptanib which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA09, fosinopril, Eplerenone may increase the hyperkalemic activities of Fosinopril.]
[S01EX01, guanethidine, Eplerenone may increase the excretion rate of Guanethidine which could result in a lower serum level and potentially a reduction in efficacy.]
[L02AE03, goserelin, Eplerenone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.]
[P01BX01, halofantrine, The metabolism of Halofantrine can be decreased when combined with Eplerenone.]
[N05AD01, haloperidol, The metabolism of Eplerenone can be decreased when combined with Haloperidol.]
[N01AB01, halothane, Halothane may decrease the antihypertensive activities of Eplerenone.]
[N05AH04, quetiapine, Quetiapine may increase the hypotensive activities of Eplerenone.]
[N06BX13, idebenone, Eplerenone may increase the excretion rate of Idebenone which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Eplerenone.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Eplerenone.]
[M04AA01, allopurinol, Eplerenone may increase the excretion rate of Allopurinol which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA01, losartan, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Losartan.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Heparin.]
[B05CB03, magnesium citrate, The risk or severity of adverse effects can be increased when Eplerenone is combined with Magnesium citrate.]
[G03DC01, allylestrenol, Eplerenone may increase the excretion rate of Allylestrenol which could result in a lower serum level and potentially a reduction in efficacy.]
[A07EC02, mesalamine, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Eplerenone.]
[C01CE02, milrinone, Eplerenone may increase the excretion rate of Milrinone which could result in a lower serum level and potentially a reduction in efficacy.]
[A12CD02, sodium monofluorophosphate, The risk or severity of adverse effects can be increased when Eplerenone is combined with Sodium fluorophosphate.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Eplerenone.]
[R03CC05, hexoprenaline, Hexoprenaline may decrease the antihypertensive activities of Eplerenone.]
[J05AG01, nevirapine, The metabolism of Eplerenone can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Eplerenone can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Eplerenone.]
[C09AA04, perindopril, Eplerenone may increase the hyperkalemic activities of Perindopril.]
[C02DB02, hydralazine, Eplerenone may increase the excretion rate of Hydralazine which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Eplerenone can be increased when used in combination with Hydrochlorothiazide.]
[R05DA03, hydrocodone, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Hydrocodone.]
[S02BA01, hydrocortisone, The metabolism of Hydrocortisone can be decreased when combined with Eplerenone.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Eplerenone can be increased when used in combination with Hydroflumethiazide.]
[B05XA17, potassium acetate, The risk or severity of hyperkalemia can be increased when Potassium acetate is combined with Eplerenone.]
[S01XA07, aluminum potassium sulfate, The risk or severity of hyperkalemia can be increased when Potassium alum is combined with Eplerenone.]
[A12BA02, potassium citrate, The risk or severity of hyperkalemia can be increased when Potassium citrate is combined with Eplerenone.]
[V03AB33, hydroxocobalamin, Eplerenone may increase the excretion rate of Hydroxocobalamin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD06, propiverine, Eplerenone may increase the excretion rate of Propiverine which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA07, hetastarch, Eplerenone may increase the excretion rate of Hydroxyethyl Starch which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BB01, hydroxyzine, The metabolism of Eplerenone can be decreased when combined with Hydroxyzine.]
[C02AC06, rilmenidine, Rilmenidine may decrease the antihypertensive activities of Eplerenone.]
[R02AX02, ibuprofen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Eplerenone.]
[B05XA08, sodium acetate, Eplerenone may increase the excretion rate of Sodium acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AD21, sodium tartrate, The risk or severity of adverse effects can be increased when Eplerenone is combined with Sodium tartrate.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Eplerenone.]
[N01AH03, sufentanil, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Sufentanil.]
[N06AA02, imipramine, Eplerenone may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Eplerenone.]
[R01AD07, tixocortol, Eplerenone may increase the excretion rate of Tixocortol which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Eplerenone.]
[L01CE01, topotecan, Eplerenone may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA11, indapamide, The therapeutic efficacy of Indapamide can be increased when used in combination with Eplerenone.]
[S01BC01, indomethacin, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Eplerenone.]
[C02CA02, indoramin, Indoramin may decrease the antihypertensive activities of Eplerenone.]
[A11HA07, inositol, Eplerenone may increase the excretion rate of Inositol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX17, milnacipran, The metabolism of Eplerenone can be decreased when combined with Milnacipran.]
[S01XA28, varenicline, Eplerenone may increase the excretion rate of Varenicline which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH01, sitagliptin, Eplerenone may increase the excretion rate of Sitagliptin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA12, alprazolam, Eplerenone may increase the excretion rate of Alprazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH02, ramelteon, Eplerenone may increase the excretion rate of Ramelteon which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA06, cerivastatin, The metabolism of Eplerenone can be decreased when combined with Cerivastatin.]
[C07AA01, alprenolol, Eplerenone may increase the hypotensive activities of Alprenolol.]
[V03AB01, ipecac, Eplerenone may increase the excretion rate of Ipecac which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA13, iprindole, Iprindole may decrease the antihypertensive activities of Eplerenone.]
[N06AF05, iproniazid, Iproniazid may increase the hypotensive activities of Eplerenone.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypotensive activities of Eplerenone.]
[S01EC03, dorzolamide, Eplerenone may increase the hypotensive activities of Dorzolamide.]
[R03CC06, isoetharine, Isoetharine may decrease the antihypertensive activities of Eplerenone.]
[C09AA16, imidapril, Eplerenone may increase the hyperkalemic activities of Imidapril.]
[N01AB06, isoflurane, Isoflurane may decrease the antihypertensive activities of Eplerenone.]
[J04AC01, isoniazid, The metabolism of Eplerenone can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Eplerenone may increase the excretion rate of Inosine pranobex which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CB01, isoproterenol, Isoprenaline may decrease the antihypertensive activities of Eplerenone.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Eplerenone is combined with Isosorbide dinitrate.]
[D10BA01, isotretinoin, Eplerenone may increase the excretion rate of Isotretinoin which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AA01, isoxsuprine, Isoxsuprine may decrease the antihypertensive activities of Eplerenone.]
[L04AC07, tocilizumab, The metabolism of Eplerenone can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Eplerenone may increase the excretion rate of Ketamine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02KD01, ketanserin, Eplerenone may increase the hypotensive activities of Ketanserin.]
[B01AC22, prasugrel, Eplerenone may increase the excretion rate of Prasugrel which could result in a lower serum level and potentially a reduction in efficacy.]
[J02AB02, ketoconazole, The metabolism of Eplerenone can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The risk or severity of adverse effects can be increased when Olanzapine is combined with Eplerenone.]
[M02AA10, ketoprofen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ketoprofen is combined with Eplerenone.]
[L04AA24, abatacept, The metabolism of Eplerenone can be increased when combined with Abatacept.]
[C01CA22, arbutamine, Arbutamine may decrease the antihypertensive activities of Eplerenone.]
[N04BC09, rotigotine, Rotigotine may decrease the antihypertensive activities of Eplerenone.]
[M01AE11, tiaprofenic acid, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tiaprofenic acid is combined with Eplerenone.]
[C07AG01, labetalol, Eplerenone may increase the excretion rate of Labetalol which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BB01, amantadine, Eplerenone may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AA05, deserpidine, Eplerenone may increase the hypotensive activities of Deserpidine.]
[A06AD11, lactulose, The risk or severity of adverse effects can be increased when Eplerenone is combined with Lactulose.]
[A06AX03, lubiprostone, The risk or severity of adverse effects can be increased when Eplerenone is combined with Lubiprostone.]
[C03CC01, ethacrynic acid, The risk or severity of adverse effects can be increased when Eplerenone is combined with Etacrynic acid.]
[G03AD01, levonorgestrel, The metabolism of Eplerenone can be decreased when combined with Levonorgestrel.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Eplerenone is combined with Levodopa.]
[S02DA01, lidocaine, The metabolism of Eplerenone can be decreased when combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Lidoflazine.]
[N06BA13, armodafinil, The metabolism of Eplerenone can be increased when combined with Armodafinil.]
[C03DB01, amiloride, The risk or severity of hyperkalemia can be increased when Amiloride is combined with Eplerenone.]
[N02CA07, lisuride, Lisuride may decrease the antihypertensive activities of Eplerenone.]
[N06AA07, lofepramine, Lofepramine may decrease the antihypertensive activities of Eplerenone.]
[A07DA03, loperamide, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Loperamide.]
[N05BA06, lorazepam, Eplerenone may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA02, lovastatin, The metabolism of Eplerenone can be decreased when combined with Lovastatin.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Eplerenone.]
[B05XA11, magnesium chloride, Eplerenone may increase the excretion rate of Magnesium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BX01, magnesium hydroxide, The risk or severity of adverse effects can be increased when Eplerenone is combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The risk or severity of adverse effects can be increased when Eplerenone is combined with Magnesium oxide.]
[V04CC02, magnesium sulfate, The risk or severity of adverse effects can be increased when Eplerenone is combined with Magnesium sulfate.]
[L01BA05, pralatrexate, Eplerenone may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA03, nilotinib, The metabolism of Eplerenone can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The risk or severity of adverse effects can be increased when Eplerenone is combined with Mannitol.]
[N06AA21, maprotiline, Eplerenone may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.]
[C02BB01, mecamylamine, Eplerenone may increase the excretion rate of Mecamylamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA18, meclofenamic acid, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Meclofenamic acid is combined with Eplerenone.]
[C01AA08, medigoxin, Eplerenone may decrease the excretion rate of Metildigoxin which could result in a higher serum level.]
[A06AB07, cascara sagrada, The risk or severity of adverse effects can be increased when Eplerenone is combined with Frangula purshiana bark.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Dalteparin.]
[N06DX01, memantine, Eplerenone may increase the excretion rate of Memantine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AB02, meperidine, Eplerenone may increase the excretion rate of Meperidine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA11, mephentermine, Mephentermine may decrease the antihypertensive activities of Eplerenone.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Eplerenone.]
[N01BB03, mepivacaine, Eplerenone may increase the excretion rate of Mepivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX05, meptazinol, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Meptazinol.]
[G04BX16, tiopronin, Eplerenone may increase the excretion rate of Tiopronin which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BC01, mersalyl, Eplerenone may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX13, paliperidone, Eplerenone may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA09, metaraminol, Metaraminol may decrease the antihypertensive activities of Eplerenone.]
[A10BA02, metformin, Eplerenone may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.]
[N07BC02, methadone, Eplerenone may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BA03, methamphetamine, Eplerenone may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF05, lamivudine, Eplerenone may increase the excretion rate of Lamivudine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Eplerenone is combined with Methazolamide.]
[G02CB05, metergoline, Metergoline may decrease the antihypertensive activities of Eplerenone.]
[H03BB02, methimazole, The metabolism of Eplerenone can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Eplerenone may increase the excretion rate of Pemetrexed which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Eplerenone.]
[A11HA02, pyridoxine, Eplerenone may increase the excretion rate of Pyridoxine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Eplerenone is combined with Ziconotide.]
[L04AX03, methotrexate, Eplerenone may increase the excretion rate of Methotrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AA02, methotrimeprazine, Methotrimeprazine may decrease the antihypertensive activities of Eplerenone.]
[C01CA10, methoxamine, Methoxamine may decrease the antihypertensive activities of Eplerenone.]
[D05BA02, methoxsalen, Eplerenone may increase the excretion rate of Methoxsalen which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG09, methoxyflurane, Methoxyflurane may decrease the antihypertensive activities of Eplerenone.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Eplerenone can be increased when used in combination with Methyclothiazide.]
[A06AC06, methylcellulose, The risk or severity of adverse effects can be increased when Eplerenone is combined with Methylcellulose.]
[C02AB01, methyldopa, Eplerenone may increase the excretion rate of Methyldopa which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CG05, methylene blue, Methylene blue may increase the hypotensive activities of Eplerenone.]
[G02AB01, methylergonovine, Methylergometrine may decrease the antihypertensive activities of Eplerenone.]
[N06BA04, methylphenidate, Methylphenidate may decrease the antihypertensive activities of Eplerenone.]
[G03EK01, methyltestosterone, Eplerenone may increase the excretion rate of Methyltestosterone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA04, methysergide, Methysergide may decrease the antihypertensive activities of Eplerenone.]
[A03FA01, metoclopramide, Eplerenone may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA08, metolazone, Eplerenone may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Eplerenone may increase the excretion rate of Metoprolol which could result in a lower serum level and potentially a reduction in efficacy.]
[P01AB01, metronidazole, The metabolism of Metronidazole can be decreased when combined with Eplerenone.]
[V04CD01, metyrapone, Eplerenone may increase the excretion rate of Metyrapone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX03, mianserin, Mianserin may decrease the antihypertensive activities of Eplerenone.]
[S02AA13, miconazole, The metabolism of Eplerenone can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aminophenazone is combined with Eplerenone.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Parnaparin.]
[N05CD08, midazolam, Eplerenone may increase the excretion rate of Midazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA17, midodrine, Midodrine may decrease the antihypertensive activities of Eplerenone.]
[G03XB01, mifepristone, The metabolism of Eplerenone can be decreased when combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Tinzaparin.]
[A06AA01, mineral oil, The risk or severity of adverse effects can be increased when Eplerenone is combined with Mineral oil.]
[J05AH01, zanamivir, Eplerenone may increase the excretion rate of Zanamivir which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA03, valsartan, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Valsartan.]
[D11AX01, minoxidil, Minoxidil may increase the hypotensive activities of Eplerenone.]
[L01XX23, mitotane, The metabolism of Eplerenone can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, Lisdexamfetamine may decrease the antihypertensive activities of Eplerenone.]
[L03AC01, aldesleukin, Eplerenone may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01DX12, molsidomine, Molsidomine may increase the hypotensive activities of Eplerenone.]
[C01BD01, amiodarone, The metabolism of Eplerenone can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, Eplerenone may increase the excretion rate of Amitriptyline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AA01, morphine, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Morphine.]
[A04AA05, palonosetron, Eplerenone may increase the excretion rate of Palonosetron which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AB05, certolizumab pegol, The metabolism of Eplerenone can be increased when combined with Certolizumab pegol.]
[G04BA01, ammonium chloride, Eplerenone may increase the excretion rate of Ammonium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA06, mycophenolic acid, Eplerenone may increase the excretion rate of Mycophenolic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Eplerenone.]
[G04CA04, silodosin, The risk or severity of orthostatic hypotension and dizziness can be increased when Eplerenone is combined with Silodosin.]
[N06AA17, amoxapine, Amoxapine may decrease the antihypertensive activities of Eplerenone.]
[N03AB05, fosphenytoin, The metabolism of Eplerenone can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, Eplerenone may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CA04, amoxicillin, Eplerenone may increase the excretion rate of Amoxicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Eplerenone.]
[N02AF02, nalbuphine, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Eplerenone can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Naltrexone.]
[L04AC03, anakinra, The metabolism of Eplerenone can be increased when combined with Anakinra.]
[S01GA01, naphazoline, Naphazoline may decrease the antihypertensive activities of Eplerenone.]
[N06BA01, amphetamine, Eplerenone may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA12, naproxen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Eplerenone.]
[A10BG01, troglitazone, The metabolism of Eplerenone can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Eplerenone is combined with Duloxetine.]
[N04BX01, tolcapone, Eplerenone may increase the excretion rate of Tolcapone which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Eplerenone.]
[N01AH06, remifentanil, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Remifentanil.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Eplerenone is combined with Levosimendan.]
[B01AC17, tirofiban, Eplerenone may increase the excretion rate of Tirofiban which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX14, iloperidone, Iloperidone may decrease the antihypertensive activities of Eplerenone.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Eplerenone.]
[S01AA19, ampicillin, Eplerenone may increase the excretion rate of Ampicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AX16, plerixafor, Eplerenone may increase the excretion rate of Plerixafor which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX23, desvenlafaxine, The metabolism of Eplerenone can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Telmisartan.]
[J05AB11, valacyclovir, Eplerenone may increase the excretion rate of Valaciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CE01, inamrinone, Eplerenone may increase the excretion rate of Amrinone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF02, nialamide, Nialamide may increase the hypotensive activities of Eplerenone.]
[C08CA04, nicardipine, The metabolism of Eplerenone can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, Nicergoline may decrease the antihypertensive activities of Eplerenone.]
[C08CA05, nifedipine, Eplerenone may increase the excretion rate of Nifedipine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA17, niflumic acid, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Niflumic acid is combined with Eplerenone.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Eplerenone is combined with Amyl Nitrite.]
[C08CA06, nimodipine, Nimodipine may increase the hypotensive activities of Eplerenone.]
[C08CA07, nisoldipine, Eplerenone may increase the excretion rate of Nisoldipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA08, nitrendipine, Eplerenone may increase the hypotensive activities of Nitrendipine.]
[R07AX01, nitric oxide, Eplerenone may increase the excretion rate of Nitric Oxide which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XE01, nitrofurantoin, Eplerenone may increase the excretion rate of Nitrofurantoin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF03, zaleplon, Eplerenone may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC05, pramipexole, Eplerenone may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DD01, nitroprusside, Eplerenone may increase the excretion rate of Nitroprusside which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AX13, nitrous oxide, Nitrous oxide may decrease the antihypertensive activities of Eplerenone.]
[C01CA03, norepinephrine, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Eplerenone.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be decreased when combined with Eplerenone.]
[C02KX01, bosentan, Bosentan may increase the hypotensive activities of Eplerenone.]
[N06AA10, nortriptyline, Nortriptyline may decrease the antihypertensive activities of Eplerenone.]
[G02CA02, nylidrin, Nylidrin may decrease the antihypertensive activities of Eplerenone.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Reviparin.]
[L04AC04, rilonacept, The metabolism of Eplerenone can be increased when combined with Rilonacept.]
[N06AA05, opipramol, Opipramol may decrease the antihypertensive activities of Eplerenone.]
[N02AA02, opium, Eplerenone may increase the excretion rate of Opium which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CB03, metaproterenol, Orciprenaline may decrease the antihypertensive activities of Eplerenone.]
[G04CA02, tamsulosin, Eplerenone may increase the excretion rate of Tamsulosin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01AC01, ouabain, Eplerenone may decrease the excretion rate of Ouabain which could result in a higher serum level.]
[J01CF04, oxacillin, Eplerenone may increase the excretion rate of Oxacillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA04, oxazepam, Eplerenone may increase the excretion rate of Oxazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AA02, oxprenolol, Eplerenone may increase the hypotensive activities of Oxprenolol.]
[N02AA05, oxycodone, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Oxycodone.]
[C01DX03, oxyfedrine, Oxyfedrine may decrease the antihypertensive activities of Eplerenone.]
[S01GA04, oxymetazoline, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Oxymetazoline.]
[N02AA11, oxymorphone, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Oxymorphone.]
[S01BC02, oxyphenbutazone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Oxyphenbutazone is combined with Eplerenone.]
[N05AH05, asenapine, Asenapine may decrease the antihypertensive activities of Eplerenone.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Danaparoid.]
[N02AX06, tapentadol, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Tapentadol.]
[J04AB30, capreomycin, Eplerenone may increase the excretion rate of Capreomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Eplerenone is combined with Papaverine.]
[H02AB05, paramethasone, The metabolism of Eplerenone can be increased when combined with Paramethasone.]
[C02KC01, pargyline, Pargyline may increase the hypotensive activities of Eplerenone.]
[G04BD11, fesoterodine, Eplerenone may increase the excretion rate of Fesoterodine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AA23, penbutolol, Eplerenone may increase the excretion rate of Penbutolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AG03, penfluridol, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Penfluridol.]
[J01CE09, penicillin G procaine, Eplerenone may increase the excretion rate of Procaine benzylpenicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AD01, pentazocine, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Pentazocine.]
[N05CA01, pentobarbital, The metabolism of Eplerenone can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Eplerenone may increase the excretion rate of Pentostatin which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AD03, pentoxifylline, Pentoxifylline may increase the hypotensive activities of Eplerenone.]
[N04BC02, pergolide, Pergolide may decrease the antihypertensive activities of Eplerenone.]
[C08EX02, perhexiline, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Perhexiline.]
[N02AD02, phenazocine, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Phenazocine.]
[G04BX06, phenazopyridine, Eplerenone may increase the excretion rate of Phenazopyridine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF03, phenelzine, Phenelzine may increase the hypotensive activities of Eplerenone.]
[N03AA02, phenobarbital, The metabolism of Eplerenone can be increased when combined with Phenobarbital.]
[A06AB01, oxyphenisatin, The risk or severity of adverse effects can be increased when Eplerenone is combined with Oxyphenisatin.]
[N01AH04, phenoperidine, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Phenoperidine.]
[C04AX02, phenoxybenzamine, Phenoxybenzamine may decrease the antihypertensive activities of Eplerenone.]
[A08AA01, phentermine, Phentermine may decrease the antihypertensive activities of Eplerenone.]
[V03AB36, phentolamine, Eplerenone may increase the excretion rate of Phentolamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA01, phenylbutazone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Phenylbutazone is combined with Eplerenone.]
[S01GA05, phenylephrine, Phenylephrine may decrease the antihypertensive activities of Eplerenone.]
[R01BA01, phenylpropanolamine, Phenylpropanolamine may decrease the antihypertensive activities of Eplerenone.]
[N03AB02, phenytoin, The metabolism of Eplerenone can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Eplerenone can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, Eplerenone may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[B02BA01, vitamin K1, Eplerenone may increase the excretion rate of Phylloquinone which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AB12, cidofovir, Eplerenone may increase the excretion rate of Cidofovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CX01, mibefradil, The metabolism of Eplerenone can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Eplerenone.]
[C07AA03, pindolol, Eplerenone may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Eplerenone.]
[J01CA12, piperacillin, Eplerenone may increase the excretion rate of Piperacillin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE01, saquinavir, The metabolism of Eplerenone can be decreased when combined with Saquinavir.]
[N06BX03, piracetam, Eplerenone may increase the excretion rate of Piracetam which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA02, eprosartan, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Eprosartan.]
[N02AC03, pirinitramide, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Piritramide.]
[S01BC06, piroxicam, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Piroxicam is combined with Eplerenone.]
[N02CX01, pizotyline, Pizotifen may decrease the antihypertensive activities of Eplerenone.]
[J05AG02, delavirdine, The metabolism of Eplerenone can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Irbesartan.]
[A10BG02, rosiglitazone, Eplerenone may increase the excretion rate of Rosiglitazone which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AD15, polyethylene glycols, The risk or severity of adverse effects can be increased when Eplerenone is combined with Polyethylene glycol.]
[L04AC08, canakinumab, The metabolism of Eplerenone can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The therapeutic efficacy of Eplerenone can be increased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The metabolism of Eplerenone can be decreased when combined with Ritonavir.]
[A10BH03, saxagliptin, Eplerenone may increase the excretion rate of Saxagliptin which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA01, potassium chloride, The risk or severity of hyperkalemia can be increased when Potassium chloride is combined with Eplerenone.]
[V03AB21, potassium iodide, The risk or severity of hyperkalemia can be increased when Potassium Iodide is combined with Eplerenone.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Eplerenone.]
[C07AB01, practolol, Eplerenone may increase the hypotensive activities of Practolol.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Eplerenone.]
[C02CA01, prazosin, The risk or severity of hypotension can be increased when Prazosin is combined with Eplerenone.]
[H02AB07, prednisone, Eplerenone may increase the excretion rate of Prednisone which could result in a lower serum level and potentially a reduction in efficacy.]
[C01DX02, prenylamine, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Prenylamine.]
[P01BA03, primaquine, The metabolism of Eplerenone can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Eplerenone can be increased when combined with Primidone.]
[M04AB01, probenecid, Eplerenone may increase the excretion rate of Probenecid which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BA02, procainamide, Eplerenone may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[S01HA05, procaine, Procaine may increase the hypotensive activities of Eplerenone.]
[L01XB01, procarbazine, Procarbazine may increase the hypotensive activities of Eplerenone.]
[C10AB05, fenofibrate, Eplerenone may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.]
[G03DA04, progesterone, The metabolism of Eplerenone can be decreased when combined with Progesterone.]
[N05AA03, promazine, Promazine may decrease the antihypertensive activities of Eplerenone.]
[R06AD02, promethazine, Eplerenone may increase the excretion rate of Promethazine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BC03, propafenone, Propafenone may decrease the antihypertensive activities of Eplerenone.]
[A03AB05, propantheline, Eplerenone may increase the excretion rate of Propantheline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC01, periciazine, Periciazine may decrease the antihypertensive activities of Eplerenone.]
[N05CM06, propiomazine, Propiomazine may decrease the antihypertensive activities of Eplerenone.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Eplerenone.]
[N01AX10, propofol, Propofol may decrease the antihypertensive activities of Eplerenone.]
[N02AC04, propoxyphene, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Dextropropoxyphene.]
[C07AA05, propranolol, Eplerenone may increase the excretion rate of Propranolol which could result in a lower serum level and potentially a reduction in efficacy.]
[C01AB01, proscillaridin, Eplerenone may decrease the excretion rate of Proscillaridin which could result in a higher serum level.]
[N02CC04, rizatriptan, Eplerenone may increase the excretion rate of Rizatriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC09, epoprostenol, Epoprostenol may increase the hypotensive activities of Eplerenone.]
[N06AA11, protriptyline, Protriptyline may decrease the antihypertensive activities of Eplerenone.]
[R01BA02, pseudoephedrine, Pseudoephedrine may decrease the antihypertensive activities of Eplerenone.]
[N05AX12, aripiprazole, The risk or severity of hypotension can be increased when Aripiprazole is combined with Eplerenone.]
[N07XX07, dalfampridine, Eplerenone may increase the excretion rate of Dalfampridine which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CC01, pyrantel, Eplerenone may increase the excretion rate of Pyrantel which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AK01, pyrazinamide, Eplerenone may increase the excretion rate of Pyrazinamide which could result in a lower serum level and potentially a reduction in efficacy.]
[A12BA05, potassium gluconate, The risk or severity of hyperkalemia can be increased when Potassium gluconate is combined with Eplerenone.]
[P01AX05, quinacrine, The metabolism of Quinacrine can be decreased when combined with Eplerenone.]
[C01BA01, quinidine, The metabolism of Quinidine can be decreased when combined with Eplerenone.]
[P01BC01, quinine, Quinine may increase the hypotensive activities of Eplerenone.]
[A02BA02, ranitidine, Eplerenone may increase the excretion rate of Ranitidine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AA01, rescinnamine, Eplerenone may increase the hyperkalemic activities of Rescinnamine.]
[C02AA02, reserpine, Eplerenone may increase the excretion rate of Reserpine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AP01, ribavirin, Eplerenone may increase the excretion rate of Ribavirin which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AB02, rifampin, The metabolism of Eplerenone can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, Rimiterol may decrease the antihypertensive activities of Eplerenone.]
[G02CA01, ritodrine, Ritodrine may decrease the antihypertensive activities of Eplerenone.]
[N02BA05, salicylamide, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylamide is combined with Eplerenone.]
[A07EC01, sulfasalazine, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Eplerenone.]
[S01BC08, salicylic acid, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylic acid is combined with Eplerenone.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Eplerenone.]
[N04BD01, selegiline, Selegiline may increase the hypotensive activities of Eplerenone.]
[L01FA03, obinutuzumab, Eplerenone may increase the hypotensive activities of Obinutuzumab.]
[A12CD01, sodium fluoride, Eplerenone may increase the excretion rate of Sodium fluoride which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CC01, sorbitol, The risk or severity of adverse effects can be increased when Eplerenone is combined with Sorbitol.]
[C07AA07, sotalol, The risk or severity of adverse effects can be increased when Sotalol is combined with Eplerenone.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Eplerenone.]
[C03DA01, spironolactone, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Eplerenone.]
[V04CH02, indigo carmine, Eplerenone may increase the excretion rate of Indigotindisulfonic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CC01, chloral hydrate, Eplerenone may increase the excretion rate of Chloral hydrate which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AB02, hydrocortisone butyrate, The metabolism of Hydrocortisone butyrate can be decreased when combined with Eplerenone.]
[C01DA14, isosorbide mononitrate, Eplerenone may increase the excretion rate of Isosorbide mononitrate which could result in a lower serum level and potentially a reduction in efficacy.]
[H02CA04, levoketoconazole, The metabolism of Eplerenone can be decreased when combined with Levoketoconazole.]
[D10AX03, azelaic acid, Eplerenone may increase the excretion rate of Azelaic acid which could result in a lower serum level and potentially a reduction in efficacy.]
